Tumor HPV-E6/E7-Targeting T Cell(BGI)

N/A

Report date: 2023/07/25 17:33:42

Base Information

Drug NameTumor HPV-E6/E7-Targeting T Cell(BGI)
Drug Alias NameHPV-T(BGI)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBgi Genomics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBgi China No 1 Investment Enterprise Partnership Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A